Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’
Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’
$200.00
Amarin’s John Thero says the firm expects a jump in sales for Vascepa from potential label expansion allowing a larger patient groups with lower triglycerides than current label indications. At the same time, he notes competitors fail to show broader cardiovascular risk reduction.
Publisher: HBW
- Description
One day after Amerin’s Vascepa won an endorsement from the European Society of Cardiology and the European Atherosclerosis Society in updated dyslipidemia treatment guidelines and the US Food and Drug Administration said it will review supplemental new drug application to expand labeling for Vascepa to treat patients with lower triglyceride levels, Amerin CEO John Thero said, “People have been hearing for too long that dietary supplements ‘might work’ at the Citi Biotech Conference in Boston on 4 September. This HBW story looks at how claims since the 70’s have failed to be proved by data and the differences between dietary supplements and drugs.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
US Zantac Sales And Distribution Continue As Sanofi Tests For NDMA 
Sign up to the